AnaptysBio, Inc. (ANAB)
| Market Cap | 594.40M |
| Revenue (ttm) | 75.00M |
| Net Income (ttm) | -19.93M |
| Shares Out | 27.30M |
| EPS (ttm) | -0.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $21.72 |
| Previous Close | $22.07 |
| Change ($) | -0.35 |
| Change (%) | -1.59% |
| Day's Open | 21.94 |
| Day's Range | 20.80 - 21.91 |
| Day's Volume | 258,116 |
| 52-Week Range | 13.92 - 35.85 |
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune con...
AnaptysBio Inc's (NASDAQ: ANAB) stock seems attractive after the POPLAR data and the 30% selloff, while there are several catalysts over the next 12-18 months, according to Truist Securities. AnaptysBio...
This analyst is excited about the company's prospects.
A phoenix may well rise from the ashes of a disappointing clinical trial.
AnaptysBio's (ANAB) lead pipeline candidate, imsidolimab, fails to meet primary endpoint of a mid-stage study evaluating it in patients with auto-inflammatory disease, palmoplantar pustulosis.
The company's leading drug candidate failed to meet its primary endpoint in a phase 2 clinical trial.
AnaptysBio Inc (NASDAQ: ANAB) reports disappointing top-line data from its Phase 2 (POPLAR) trial of imsidolimab for palmoplantar pustulosis (PPP). The study failed to meet its primary endpoint of impro...
There was some encouraging news from across the Atlantic.
Perhaps no news is bad news for the ambitious biotech.
AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The biotech got a sharp upward shift in recommendation and target price from a prominent analyst.
ESSA Pharma Inc. (NASDAQ: EPIX) shares are trading higher after the company reported first-quarter earnings results and highlighted the presentation of Phase 1 pharmacology data of EPI-7386 for advanced...
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...
AnaptysBio is a $675M clinical-stage biotechnology company focused on developing immunology therapeutics based around emerging immune control mechanisms applicable to inflammation and immuno-oncology. A...
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...
SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...
AnaptysBio (ANAB) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
AnaptysBio (ANAB) reports positive top-line data from an interim analysis of its phase II GALLOP study on imsidolimab for the treatment of moderate-to-severe generalized pustular psoriasis.
SAN DIEGO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...
SAN DIEGO, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical nee...
DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates AnaptysBio, Inc.
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -5.33% and -100.00%, respectively, for the quarter ended June 2020.
SAN DIEGO, Aug. 10, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune co...
AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
SAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical need...
Dermatology Physician-Scientist To Lead Wholly-Owned Pipeline Advancement Dermatology Physician-Scientist To Lead Wholly-Owned Pipeline Advancement
Appoints Dennis Mulroy as Chief Financial Officer and Eric Loumeau as Chief Operating Officer Appoints Dennis Mulroy as Chief Financial Officer and Eric Loumeau as Chief Operating Officer
SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune co...
AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Is (ANAB) Outperforming Other Medical Stocks This Year?
The beaten-up biopharma provided an update that revved up interest in its pipeline.
NEW YORK, May 19, 2020 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. ("Anaptys" or the "Company") (NASDAQ:ANAB) of the May 26, 2020 ...
NEW YORK, May 15, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and November 7,...
As of late, it has definitely been a great time to be an investor AnaptysBio
AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Key clinical trial results this quarter will determine the better buy.
This antibody drug developer can be had for fire-sale prices.
AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
These three biopharma stocks all ended in positive territory Friday after a week of double-digit declines.
Worries about a coronavirus impact don't make sense.
A pair of black swans crushed these three healthcare stocks today.
After a rough 2019, investors are excited about the biotech's prospects in the year ahead.
AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Falling knives are companies whose share prices have declined more than 59% over the past 12 months.
AnaptysBio Is Due For A Bounce As It Trades Significantly Below Its Net Cash Per Share
AnaptysBio has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
AnaptysBio (ANAB) earnings for the antibody development company's third quarter of 2019 have ANAB stock taking a dive on Friday.
A clinical trial flop doesn't leave the biotech a lot of options.
AnaptysBio Inc (NASDAQ: ANAB) shares were taking a huge hit after the company announced a clinical pipeline update along with its third-quarter report.
AnaptysBio stock crashed Friday after the biotech said its experimental eczema treatment failed to pass muster in a Phase 2 study. Shares fell to their lowest-ever point in high volume.
About ANAB
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable t... [Read more...]
| Industry Biotechnology | IPO Date Jan 26, 2017 |
| CEO Hamza Suria | Employees 94 |
| Stock Exchange NASDAQ | Ticker Symbol ANAB |
Financial Performance
In 2020, AnaptysBio's revenue was $75.00 million, an increase of 837.50% compared to the previous year's $8.00 million. Losses were -$19.93 million, -79.52% less than in 2019.
Analyst Forecasts
According to 6 analysts, the average rating for AnaptysBio stock is "Buy." The 12-month stock price forecast is 28.50, which is an increase of 31.22% from the latest price.